Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2019

02.01.2019 | How I do it

A Simplified Two-Step Technique for Extended Lymphadenectomy During Resection of Gastroesophageal Malignancy: Early Results Compared to En Bloc Dissection

verfasst von: Michael J. Minarich, Roderich E. Schwarz

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Extended lymph node dissection (ELND) remains an important component of curative intent resection of mid-stage gastric cancer (GC). Benefits include enhanced staging accuracy, extending regional disease control, and optimizing potential curability. ELND during gastrectomy remains underutilized in US centers due to a low prevalence of GC operations.

Methods

The traditional en bloc ELND was modified into a two-step technique to facilitate greater ease of dissection with better exposure. After completion of the gastrectomy component, retrogastric nodes are dissected in a separate, contiguous specimen. Resulting data were compared to outcomes after en bloc resection.

Results

Of 179 consecutive patients undergoing gastrectomy, 129 underwent an ELND (73%). There were 97 men and 32 women, with a median age of 64 years (range 24–98). The median total LN count was 25 (3–86). The two-step dissection yielded an average of 18.3 (± 8.5 S.D.) perigastric and 12.1 (± 5.8) retrogastric nodes. Two-step LND was associated with lower estimated blood loss (265 vs. 448 ml, p = 0.0005), lower transfusion requirements (6 vs. 28%, p = 0.007), greater mean total LN counts (30 vs. 26, p = 0.03), and a greater rate of obtaining at least 15 or 20 LNs (91 vs. 77% and 83 vs. 65%, p = 0.05). Major morbidity (overall 16%), length of stay, and survival outcomes were not different.

Conclusions

The two-step LND technique as described was found to be associated with favorable operative and postoperative outcome parameters and an excellent LN yield. It can be recommended for standard ELND indications in the absence of macroscopically abnormal LNs.
Literatur
1.
Zurück zum Zitat Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst Sep 1 2017;109(9):1–22. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst Sep 1 2017;109(9):1–22.
2.
Zurück zum Zitat Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg Oct 2014;219(4):664–675.CrossRefPubMed Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg Oct 2014;219(4):664–675.CrossRefPubMed
3.
Zurück zum Zitat Ajani JA, D'Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw Oct 2016;14(10):1286–1312.CrossRef Ajani JA, D'Amico TA, Almhanna K, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw Oct 2016;14(10):1286–1312.CrossRef
4.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med Jul 6 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med Jul 6 2006;355(1):11–20.CrossRefPubMed
5.
Zurück zum Zitat Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol Sep 2015;16(9):1090–1098.CrossRefPubMed Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol Sep 2015;16(9):1090–1098.CrossRefPubMed
6.
Zurück zum Zitat Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol Feb 2014;21(2):569–574.CrossRefPubMed Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol Feb 2014;21(2):569–574.CrossRefPubMed
7.
Zurück zum Zitat Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg Apr 2015;19(4):782–788.CrossRefPubMed Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg Apr 2015;19(4):782–788.CrossRefPubMed
8.
Zurück zum Zitat Biondi A, Persiani R, Cananzi F, et al. R0 resection in the treatment of gastric cancer: room for improvement World J Gastroenterol Jul 21 2010;16(27):3358–3370.CrossRefPubMedPubMedCentral Biondi A, Persiani R, Cananzi F, et al. R0 resection in the treatment of gastric cancer: room for improvement World J Gastroenterol Jul 21 2010;16(27):3358–3370.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol Oct 1 2005;23(28):7114–7124.CrossRefPubMed Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol Oct 1 2005;23(28):7114–7124.CrossRefPubMed
10.
Zurück zum Zitat Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol Feb 2007;14(2):317–328.CrossRefPubMed Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol Feb 2007;14(2):317–328.CrossRefPubMed
11.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th edition. New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th edition. New York: Springer; 2010.
12.
Zurück zum Zitat Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol May 2010;11(5):439–449.CrossRefPubMed Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol May 2010;11(5):439–449.CrossRefPubMed
13.
Zurück zum Zitat Jin LX, Moses LE, Squires MH, 3rd, et al. Factors Associated With Recurrence and Survival in Lymph Node-negative Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg Dec 2015;262(6):999–1005.CrossRefPubMed Jin LX, Moses LE, Squires MH, 3rd, et al. Factors Associated With Recurrence and Survival in Lymph Node-negative Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg Dec 2015;262(6):999–1005.CrossRefPubMed
14.
Zurück zum Zitat Morgan JW, Ji L, Friedman G, Senthil M, Dyke C, Lum SS. The role of the cancer center when using lymph node count as a quality measure for gastric cancer surgery. JAMA Surg Jan 2015;150(1):37–43.CrossRefPubMed Morgan JW, Ji L, Friedman G, Senthil M, Dyke C, Lum SS. The role of the cancer center when using lymph node count as a quality measure for gastric cancer surgery. JAMA Surg Jan 2015;150(1):37–43.CrossRefPubMed
15.
Zurück zum Zitat Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer Mar 1999;79(9–10):1522–1530.CrossRefPubMedPubMedCentral Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer Mar 1999;79(9–10):1522–1530.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg. Dec 2002;195(6):855–864.CrossRefPubMed Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg. Dec 2002;195(6):855–864.CrossRefPubMed
17.
Zurück zum Zitat Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol Jun 1 2004;22(11):2069–2077.CrossRefPubMed Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol Jun 1 2004;22(11):2069–2077.CrossRefPubMed
18.
Zurück zum Zitat Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg Apr 2010;251(4):640–646.CrossRefPubMed Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg Apr 2010;251(4):640–646.CrossRefPubMed
19.
Zurück zum Zitat Wong J, Rahman S, Saeed N, et al. Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience. J Gastrointest Surg Mar 2014;18(3):505–511.CrossRefPubMed Wong J, Rahman S, Saeed N, et al. Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience. J Gastrointest Surg Mar 2014;18(3):505–511.CrossRefPubMed
20.
Zurück zum Zitat Shinohara H, Kurahashi Y, Haruta S, Ishida Y, Sasako M. Universalization of the operative strategy by systematic mesogastric excision for stomach cancer with that for total mesorectal excision and complete mesocolic excision colorectal counterparts. Ann Gastroenterol Surg 2018;2(1):28–36.CrossRefPubMed Shinohara H, Kurahashi Y, Haruta S, Ishida Y, Sasako M. Universalization of the operative strategy by systematic mesogastric excision for stomach cancer with that for total mesorectal excision and complete mesocolic excision colorectal counterparts. Ann Gastroenterol Surg 2018;2(1):28–36.CrossRefPubMed
21.
Zurück zum Zitat Schwarz RE. Spleen-preserving splenic hilar lymphadenectomy at the time of gastrectomy for cancer: technical feasibility and early results. J Surg Oncol Jan 2002;79(1):73–76.CrossRefPubMed Schwarz RE. Spleen-preserving splenic hilar lymphadenectomy at the time of gastrectomy for cancer: technical feasibility and early results. J Surg Oncol Jan 2002;79(1):73–76.CrossRefPubMed
22.
Zurück zum Zitat Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg Sep 1984;119(9):1067–1072.CrossRefPubMed Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg Sep 1984;119(9):1067–1072.CrossRefPubMed
23.
Zurück zum Zitat Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg May 2010;97(5):643–649.CrossRefPubMed Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg May 2010;97(5):643–649.CrossRefPubMed
24.
Zurück zum Zitat Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol Apr 2006;7(4):309–315.CrossRefPubMed Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol Apr 2006;7(4):309–315.CrossRefPubMed
25.
Zurück zum Zitat Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients [see comments]. Lancet. 1995;345(8952):745–748.CrossRefPubMed Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients [see comments]. Lancet. 1995;345(8952):745–748.CrossRefPubMed
26.
Zurück zum Zitat de Steur WO, Hartgrink HH, Dikken JL, Putter H, van de Velde CJ. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg Oct 2015;102(11):1388–1393.CrossRefPubMed de Steur WO, Hartgrink HH, Dikken JL, Putter H, van de Velde CJ. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg Oct 2015;102(11):1388–1393.CrossRefPubMed
27.
Zurück zum Zitat Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg Jan 2014;101(2):23–31.CrossRefPubMed Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg Jan 2014;101(2):23–31.CrossRefPubMed
28.
Zurück zum Zitat Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg Nov 2007;11(11):1384–1393; discussion 1393-1384. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg Nov 2007;11(11):1384–1393; discussion 1393-1384.
29.
Zurück zum Zitat Naffouje SA, Salti GI. Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database. J Gastric Cancer Dec 2017;17(4):319–330.CrossRefPubMedPubMedCentral Naffouje SA, Salti GI. Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database. J Gastric Cancer Dec 2017;17(4):319–330.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Mirkin KA, Hollenbeak CS, Wong J. Greater Lymph Node Retrieval Improves Survival in Node-Negative Resected Gastric Cancer in the United States. J Gastric Cancer Dec 2017;17(4):306–318.CrossRefPubMedPubMedCentral Mirkin KA, Hollenbeak CS, Wong J. Greater Lymph Node Retrieval Improves Survival in Node-Negative Resected Gastric Cancer in the United States. J Gastric Cancer Dec 2017;17(4):306–318.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol May 2018;19(5):616–628.CrossRefPubMed Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol May 2018;19(5):616–628.CrossRefPubMed
32.
Zurück zum Zitat In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol Nov 2017;24(12):3683–3691.CrossRefPubMed In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol Nov 2017;24(12):3683–3691.CrossRefPubMed
33.
Zurück zum Zitat Randle RW, Swords DS, Levine EA, et al. Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative. J Surg Oncol Jun 2016;113(7):750–755.CrossRefPubMedPubMedCentral Randle RW, Swords DS, Levine EA, et al. Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative. J Surg Oncol Jun 2016;113(7):750–755.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Gholami S, Janson L, Worhunsky DJ, et al. Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. J Am Coll Surg Aug 2015;221(2):291–299.CrossRefPubMedPubMedCentral Gholami S, Janson L, Worhunsky DJ, et al. Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. J Am Coll Surg Aug 2015;221(2):291–299.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Glenn JA, Turaga KK, Gamblin TC, Hohmann SF, Johnston FM. Minimally invasive gastrectomy for cancer: current utilization in US academic medical centers. Surg Endosc Dec 2015;29(12):3768–3775.CrossRefPubMed Glenn JA, Turaga KK, Gamblin TC, Hohmann SF, Johnston FM. Minimally invasive gastrectomy for cancer: current utilization in US academic medical centers. Surg Endosc Dec 2015;29(12):3768–3775.CrossRefPubMed
36.
Zurück zum Zitat Papenfuss WA, Kukar M, Oxenberg J, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol Sep 2014;21(9):3008–3014.CrossRefPubMed Papenfuss WA, Kukar M, Oxenberg J, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol Sep 2014;21(9):3008–3014.CrossRefPubMed
37.
Zurück zum Zitat Day RW, Badgwell BD, Fournier KF, Mansfield PF, Aloia TA. Defining the Impact of Surgical Approach on Perioperative Outcomes for Patients with Gastric Cardia Malignancy. J Gastrointest Surg Jan 2016;20(1):146–153; discussion 153. Day RW, Badgwell BD, Fournier KF, Mansfield PF, Aloia TA. Defining the Impact of Surgical Approach on Perioperative Outcomes for Patients with Gastric Cardia Malignancy. J Gastrointest Surg Jan 2016;20(1):146–153; discussion 153.
38.
Zurück zum Zitat Parsons HM, Begun JW, Kuntz KM, Tuttle TM, McGovern PM, Virnig BA. Lymph node evaluation for colon cancer in an era of quality guidelines: who improves? J Oncol Pract Jul 2013;9(4):e164–171. Parsons HM, Begun JW, Kuntz KM, Tuttle TM, McGovern PM, Virnig BA. Lymph node evaluation for colon cancer in an era of quality guidelines: who improves? J Oncol Pract Jul 2013;9(4):e164–171.
39.
Zurück zum Zitat Datta J, Lewis RS Jr., Mamtani R, et al. Implications of inadequate lymph node staging in resectable gastric cancer: a contemporary analysis using the National Cancer Data Base. Cancer Sep 15 2014;120(18):2855–2865.CrossRefPubMed Datta J, Lewis RS Jr., Mamtani R, et al. Implications of inadequate lymph node staging in resectable gastric cancer: a contemporary analysis using the National Cancer Data Base. Cancer Sep 15 2014;120(18):2855–2865.CrossRefPubMed
40.
Zurück zum Zitat Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study Cancer Jun 1 2002;94(11):2862–2866.CrossRefPubMed Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study Cancer Jun 1 2002;94(11):2862–2866.CrossRefPubMed
41.
Zurück zum Zitat Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med Mar 25 1999;340(12):908–914.CrossRefPubMed Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med Mar 25 1999;340(12):908–914.CrossRefPubMed
42.
Zurück zum Zitat Dikken JL, van de Velde CJ, Gonen M, Verheij M, Brennan MF, Coit DG. The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol Aug 2012;19(8):2443–2451.CrossRefPubMedPubMedCentral Dikken JL, van de Velde CJ, Gonen M, Verheij M, Brennan MF, Coit DG. The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol Aug 2012;19(8):2443–2451.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol May 1 2011;29(13):1715–1721.CrossRefPubMed Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol May 1 2011;29(13):1715–1721.CrossRefPubMed
44.
Zurück zum Zitat Smyth EC, Fassan M, Cunningham D, et al. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol Aug 10 2016;34(23):2721–2727.CrossRefPubMedPubMedCentral Smyth EC, Fassan M, Cunningham D, et al. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol Aug 10 2016;34(23):2721–2727.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Volpe CM, Driscoll DL, Douglass HO, Jr. Outcome of patients with proximal gastric cancer depends on extent of resection and number of resected lymph nodes. Ann Surg Oncol Mar 2000;7(2):139–144. Volpe CM, Driscoll DL, Douglass HO, Jr. Outcome of patients with proximal gastric cancer depends on extent of resection and number of resected lymph nodes. Ann Surg Oncol Mar 2000;7(2):139–144.
46.
Zurück zum Zitat Marcus SG, Cohen D, Lin K, et al. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg Dec 2003;7(8):1015–1022; discussion 1023. Marcus SG, Cohen D, Lin K, et al. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg Dec 2003;7(8):1015–1022; discussion 1023.
47.
Zurück zum Zitat Tuttle R, Hochwald SN, Kukar M, Ben-David K. Total laparoscopic resection for advanced gastric cancer is safe and feasible in the Western population. Surg Endosc Aug 2016;30(8):3552–3558.CrossRefPubMed Tuttle R, Hochwald SN, Kukar M, Ben-David K. Total laparoscopic resection for advanced gastric cancer is safe and feasible in the Western population. Surg Endosc Aug 2016;30(8):3552–3558.CrossRefPubMed
48.
Zurück zum Zitat Ikoma N, Chen HC, Wang X, et al. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol Sep 2017;24(9):2679–2687.CrossRefPubMed Ikoma N, Chen HC, Wang X, et al. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol Sep 2017;24(9):2679–2687.CrossRefPubMed
Metadaten
Titel
A Simplified Two-Step Technique for Extended Lymphadenectomy During Resection of Gastroesophageal Malignancy: Early Results Compared to En Bloc Dissection
verfasst von
Michael J. Minarich
Roderich E. Schwarz
Publikationsdatum
02.01.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2019
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-018-4056-7

Weitere Artikel der Ausgabe 2/2019

Journal of Gastrointestinal Surgery 2/2019 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.